I am a
Home I AM A Search Login

Papers of the Week

2020 May 16

Cochrane Database Syst Rev


Adalimumab for maintenance of remission in Crohn’s disease.


Townsend CM, Nguyen TM, Cepek J, Abbass M, Parker CE, MacDonald JK, Khanna R, Jairath V, Feagan BG
Cochrane Database Syst Rev. 2020 May 16; 5:CD012877.
PMID: 32413933.


Conventional medications for Crohn's disease (CD) include anti-inflammatory drugs, immunosuppressants and corticosteroids. If an individual does not respond, or loses response to first-line treatments, then biologic therapies such as tumour necrosis factor-alpha (TNF-α) antagonists such as adalimumab are considered for treating CD. Maintenance of remission of CD is a clinically important goal, as disease relapse can negatively affect quality of life.